Investor Presentaiton

FY2022 Future News Flow Daiichi-Sankyo As of Jul 2022 Planned regulatory submissions DESTINY-Breast04: HER2 low BC, post chemo, Ph3 Planned major publications World Conference on Lung Cancer (WCLC, Aug 6-9, 2022) Dato-DXd TROPION-Lung02: NSCLC without actionable gene mutation, Ph1b, pembrolizumab combo • Initial interim data European Society for Medical Oncology (ESMO, Sep 9-13, 2022) DS-7300 Solid tumors Ph1/2 ENHERTUⓇ Quizartinib DS-5670 • Data update Regulatory decisions DESTINY-Breast03: HER2+ BC, 2L, Ph3 • JP: FY2022 H2 • US: FY2022 H2 ENHERTU ® DESTINY-Breast04: HER2 low BC, post chemo, Ph3 DESTINY-Gastric02: HER2+ GC, 2L, Ph2 • EU: FY2022 H2 DESTINY-Lung01: HER2 mutated NSCLC, 2L, Ph2 ⚫ US: FY2022 H1 Registrational Ph2: R/R ATL/L Valemetostat • JP: FY2022 H1 • CN: FY2022 H1 QUANTUM-First • AML, 1L, Ph3 JP/US/EU: FY2022 H1 Ph1/2/3: COVID-19 mRNA vaccine, booster shot ⚫ JP: FY2022 H2 Key data readouts ENHERTUⓇ DESTINY-Breast02: HER2+ BC, 3L, Ph3 . FY2022 H1 TROPION-Lung01*: NSCLC, 2/3L, Ph3 Dato-DXd • FY2022 H2 DS-5670 Ph1/2/3: COVID-19 mRNA vaccine, booster vaccination • FY2022 H2 Planned pivotal study initiation HER3-DXd HERTHENA-Lung02: EGFR mutated NSCLC, 2L, Ph3 • FY2022 H1 Bold: update from FY2021 Q4 AML: acute myeloid leukemia, ATL/L: adult T-cell leukemia/lymphoma, BC: breast cancer, GC: gastric cancer, NSCLC: non small cell lung cancer, R/R: relapsed/refractory Timeline indicated is based on the current forecast and subject to change. *Event-driven study 37

View entire presentation